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A number of X-ray analyses of an enzyme involved in a key early stage of
tetrapyrrole biosynthesis are reported. Two structures of human 5-aminolaevu-
linate dehydratase (ALAD), native and recombinant, have been determined at
2.8 A˚ resolution, showing that the enzyme adopts an octameric quaternary
structure in accord with previously published analyses of the enzyme from a
range of other species. However, this is in contrast to the ﬁnding that a disease-
related F12L mutant of the human enzyme uniquely forms hexamers [Breinig et
al. (2003), Nature Struct. Biol. 10, 757–763]. Monomers of all ALADs adopt the
TIM-barrel fold; the subunit conformation that assembles into the octamer
includes the N-terminal tail of one monomer curled around the (/)8 barrel of a
neighbouring monomer. Both crystal forms of the human enzyme possess two
monomers per asymmetric unit, termed A and B. In the native enzyme there are
a number of distinct structural differences between the A and Bmonomers, with
the latter exhibiting greater disorder in a number of loop regions and in the
active site. In contrast, the second monomer of the recombinant enzyme appears
to be better deﬁned and the active site of both monomers clearly possesses a zinc
ion which is bound by three conserved cysteine residues. In native human
ALAD, theAmonomer also has a ligand resembling the substrate ALAwhich is
covalently bound by a Schiff base to one of the active-site lysines (Lys252) and is
held in place by an ordered active-site loop. In contrast, these features of the
active-site structure are disordered or absent in the B subunit of the native
human enzyme. The octameric structure of the zinc-dependent ALAD from the
hyperthermophile Pyrobaculum calidifontis is also reported at a somewhat
lower resolution of 3.5 A˚. Finally, the details are presented of a high-resolution
structure of the Escherichia coli ALAD enzyme co-crystallized with a
noncovalently bound moiety of the product, porphobilinogen (PBG). This
structure reveals that the pyrrole side-chain amino group is datively bound to
the active-site zinc ion and that the PBG carboxylates interact with the enzyme
via hydrogen bonds and salt bridges with invariant residues. A number of
hydrogen-bond interactions that were previously observed in the structure of
yeast ALAD with a cyclic intermediate resembling the product PBG appear to
be weaker in the new structure, suggesting that these interactions are only
optimal in the transition state.
1. Introduction
Most haem in living systems is derived from endogenous
synthesis, with each tissue producing it according to its own
needs. In humans, the bone marrow accounts for more than
ISSN 2059-7983
# 2017 International Union of Crystallography
electronic reprint
70% of total haem synthesis and is the site of incorporation of
haem into haemoglobin for the production of erythrocytes
(Ajioka et al., 2006). The liver is the second most important
site, accounting for approximately 15% of the total haem
synthesized. In this organ there is a high requirement for haem
owing to the many mitochondrial cytochromes and other
haemoproteins, such as cytochrome P450, catalase and cyto-
chrome b5.
All of the enzymes catalysing the eight steps of the haem-
biosynthesis pathway have now been analysed structurally (for
a review, see Layer et al., 2010). One of the ﬁrst enzymes to be
studied was 5-aminolaevulinic acid dehydratase (EC 4.2.1.24),
which is also referred to as porphobilinogen synthase since
it catalyses the condensation of two 5-aminolaevulinic acid
(ALA) molecules to form the pyrrole porphobilinogen (PBG;
Fig. 1; Jordan, 1991, 1994; Warren & Scott, 1990; Jaffe, 1995;
Jaffe & Lawrence, 2014; Jaffe, 2016). Four molecules of the
product of ALAD (PBG) are condensed in a reaction cata-
lysed by porphobilinogen deaminase to form the linear
tetrapyrrole preuroporphyrinogen. This is then cyclized and
rearranged by uroporphyrinogen synthase to give uro-
porphyrinogen III, the ﬁrst macrocyclic tetrapyrrole in the
pathway. These three steps from ALA to uroporphyrinogen
III are common to the biosyntheses of haem, chlorophyll,
cobalamins and all other tetrapyrroles.
Single-turnover experiments on ALAD have shown that
the ﬁrst substrate molecule to bind to the enzyme ultimately
forms the ‘propionate’ half of the product PBG, whilst the
second substrate molecule forms the ‘acetate’ half of PBG
(Jordan & Gibbs, 1985). This has led to the widely used
terminology of the ‘P’ and ‘A’ binding sites in the enzyme
which bind the substrate moieties forming the propionate and
acetate halves of the product, respectively (Fig. 1). There is
evidence that many ALADs require a metal ion for activity,
with animal enzymes using zinc and plant enzymes having
at least a partial requirement for magnesium (Jaffe, 2003).
Representatives of both classes exist in bacteria.
The gene for human ALAD is situated on chromosome
9q33.1 (Wetmur et al., 1986; Potluri et al., 1987) and contains
two alternative 50 noncoding exons, 1A and 1B, which are
followed by 11 coding exons, numbered 2 to 12 (Kaya et al.,
1994). Exon 1A is incorporated into the housekeeping tran-
script whereas 1B is incorporated into the erythroid-speciﬁc
transcript, although the proteins produced from both of these
transcripts are identical. Hereditary deﬁciencies in ALAD
are associated with the rare genetic disease Doss or ALAD
porphyria (Doss et al., 1979). This is an autosomal recessive
disorder that has severe neurological symptoms owing to the
accumulation of the substrate 5-aminolaevulinate, which
structurally resembles the neurotransmitter -aminobutyric
acid (Sassa, 1998). The zinc ions in ALAD are displaced upon
the addition of lead, a potent inhibitor of the zinc-dependent
enzymes (Jaffe et al., 2001; Simons, 1995; Warren et al., 1998).
Inhibition of ALAD by lead ions is one of the major mani-
festations of acute lead poisoning, which often leads to
neurological and psychotic disturbances. The enzyme is also
inhibited by succinylacetone, which accumulates in patients
with type I tyrosinaemia (Lindblad et al., 1977): approximately
40% of children with this disease develop porphyric symp-
toms. Relative to other enzymes in the haem-biosynthesis
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Figure 1
The reaction catalysed by 5-aminolaevulinic acid dehydratase or porphobilinogen synthase (PBGS). The two 5-aminolaevulinic acid moieties forming
the acetate (A) and propionate (P) side groups of the product, porphobilinogen, are shown. The next enzyme in the pathway, porphobilinogen
deaminase (PBGD), catalyses the condensation of four porphobilinogen moieties to form the ﬁrst linear tetrapyrrole of the pathway. The following steps
in the pathway lead ultimately to the formation of several key cyclic tetrapyrrole cofactors, including haem and chlorophyll.
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pathway, ALAD is present in large excess, for example, the
activity of ALAD in liver is 80–100 times that of the preceding
enzyme in the pathway. These effects may account for the fact
that heterozygotes for ALAD deﬁciency are asymptomatic
but are likely to be more prone to environmental or occupa-
tional lead poisoning. At least 11 mutations causing ALAD
porphyria have been identiﬁed and a signiﬁcant proportion of
sufferers are compound heterozygotes, i.e. each ALAD allele
has a different harmful mutation. Porphyria-associated
mutants of ALAD have a tendency to adopt the hexameric
state (Jaffe & Stith, 2007). There have been several reports
that ALAD co-puriﬁes with the proteasome and that it affects
the activity of these large protein complexes which catalyse
ATP-dependent proteolysis and play key roles in cell-cycle
control and homeostasis (Guo et al., 1994; Bardag-Gorce &
French, 2011). An interaction with the chaperone Hsp70 has
also been reported (Gross et al., 1999).
All ALADs typically contain around 330 residues per
subunit and are usually octameric (Jordan, 1991, 1994; Warren
& Scott, 1990; Jaffe, 1995, 2016). Studies on bovine and human
ALAD showed that catalysis occurs through the formation of
a Schiff-base link at the P-site between the 4-keto group of the
substrate and an invariant lysine residue (Lys252 in human
ALAD; Gibbs & Jordan, 1986). Later structural studies
established the importance of a second invariant lysine residue
(Lys199 in human ALAD) in forming a Schiff base with the
A-side substrate (Erskine, Senior et al., 1997; Erskine, Coates
et al., 2001). The implications of these structural studies for the
mechanism have been reviewed critically by Jaffe (2004, 2016)
as well as by Erdtman et al. (2010) and Tian et al. (2012), who
used theoretical approaches to investigate the order of bond
formation during the reaction.
The human and bovine ALAD enzymes have been puriﬁed
in high yield from both blood and liver, where the enzyme is
present in high abundance (Gibbs et al., 1985; Jordan &
Seehra, 1986). Gel-ﬁltration, sedimentation, electron-
microscopy and solution-scattering studies have shown that
the mammalian ALAD enzymes are octameric (Wu et al.,
1974; Bevan et al., 1980; Pilz et al., 1988). However, there are
reports that the plant enzyme can adopt a hexameric form
(see, for example, Kokona et al., 2008), and a hexameric,
porphyria-associated mutant form of the human enzyme has
been described (Breinig et al., 2003), leading to speculation
that interconversion between these oligomeric states provides
a means of regulating the activity of ALAD enzymes, as
corroborated by further studies (Jaffe & Lawrence, 2012).
Some zinc-dependent ALADs can bind multiple metal ions
per subunit (Jaffe et al., 1995; Spencer & Jordan, 1994). One of
the metal ions is essential for catalytic activity and another can
play an allosteric activating role. The catalytic metal-binding
site is now known to consist of three conserved zinc-binding
cysteine residues. With the exception of animals and fungi,
most zinc-dependent ALADs also contain an allosteric
magnesium site. In contrast, ALADs from plants, apicoplasts
and some prokaryotes have the allosteric magnesium site but
lack several of the active-site cysteines. Some of these ALADs
are catalytically competent in the absence of active-site metal
ions, but the activity is dramatically stimulated by the addition
of magnesium.
High-resolution X-ray structures have been determined for
ALADs from yeast (Erskine, Senior et al., 1997), Escherichia
coli (Erskine et al., 1999), Pseudomonas aeruginosa (Fran-
kenberg et al., 1999), the green sulfur bacterium Chlorobium
vibrioforme (Coates et al., 2004) and the protozoan parasite
Toxoplasma gondii (Jaffe et al., 2011). The latter enzyme
possesses extensions at the N- and C-terminal ends which form
elements of secondary structure which were not seen in earlier
structures but are clearly involved in quaternary interactions.
It also provided one of the clearest pictures of the product
porphobilinogen bound to the enzyme active site. In addition,
structures are available for mouse ALAD (PDB entries 2z0i
and 2z1b; RIKEN Structural Genomics/Proteomics Initiative,
unpublished work), the human erythrocyte enzyme (PDB
entry 1e51; N. L. Mills-Davies, D. Thompson, J. B. Cooper,
S. P. Wood & P. M. Shoolingin-Jordan, unpublished work) and
a porphyria-associated mutant of human ALAD which forms
hexamers with reduced catalytic activity (Breinig et al., 2003).
A large number of ALAD inhibitors have been structurally
characterized bound to the enzyme from various species,
including the antibiotic alaremycin which is produced by
Streptomyces and has been shown to operate by inhibiting
bacterial haem synthesis (Heinemann et al., 2010). All of these
inhibitors act by forming Schiff-base complexes with one or
both of the active-site lysines (Cooper & Erskine, 2004).
Recently, it has been suggested that a number of heterocyclic
inhibitors of ALAD have potential in treatment of infections
by ﬁlial nematodes, parasitic organisms which are unable to
synthesize tetrapyrroles and therefore rely on the endo-
symbiotic -proteobacterium Wolbachia for haem synthesis
(Lentz et al., 2013, 2014).
Pyrobaculum calidifontis strain VA1 is a hyperthermophilic
archaeon (Amo et al., 2002). Whilst the genus Pyrobaculum
has a large diversity of oxygen requirements ranging from
strictly anaerobic to obligate aerobic, this particular species is
known to be a facultative anaerobe. Interest in the oxygen
needs of this organism led us to study the enzymes responsible
for synthesis of haem, which is central to oxygen assimilation.
In this paper, we describe two previously unpublished
structure determinations of human erythrocyte ALAD using
protein puriﬁed from blood and expressed in E. coli. We also
describe the structure analysis of the P. calidifontis enzyme
(Pc-ALAD) and a high-resolution structure of E. coli ALAD
co-crystallized with a noncovalently bound moiety of the
product, porphobilinogen.
2. Methods and materials
2.1. Cloning and expression
For expression of recombinant human ALAD, a synthetic
gene of 990 base pairs encoding the 330 amino acids of human
ALAD was constructed from a total of 18 oligonucleotides:
nine primers for each strand. The primers had an overlap of
approximately ten base pairs. Only the codon specifying Pro3
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was changed, from CCC to CCG, as CCC is known to be a
weakly expressing Pro codon in E. coli. The 50 end of the gene
was engineered with an NdeI restriction site and the 30 end
with a BamHI restriction site. These restriction sites enabled
insertion of the cDNA into the vector pT7-7, which was then
transformed into the bacterial strain E. coli BL21 (DE3) and
gene expression was induced by induction with 1 mM
isopropyl -d-1-thiogalactopyranoside (IPTG).
The putative gene sequence for Pc-ALAD was obtained
from the KEGG database and was used to design primers for
ampliﬁcation of the hemB gene. The forward primer, 50-CAT-
ATGCGCGTACAGTTTCCAACGAC-30, was designed from
the N-terminal sequence of the gene with the introduction of a
cleavage site for the restriction enzyme NdeI (shown in bold)
at the 50 end of the primer. The reverse primer, 50-GCG-
CAAGGAGTAGCGCTGTTCG-30, was designed using the
C-terminal end of the gene sequence and did not contain any
restriction sites. The gene was ampliﬁed using standard PCR
methods, ligated into the vector pTZ57R/T by TA cloning
(Holton & Graham, 1991) and its orientation with respect to
the polycloning site was conﬁrmed by double restriction
digestion and sequencing. The gene was then excised from this
plasmid using NdeI and BamHI for ligation into the expres-
sion vector pET-21d which had previously been cleaved with
the same two restriction enzymes. The gene was expressed
using E. coli BL21-CodonPlus cells using standard methods
with addition of the inducer IPTG to a ﬁnal concentration of
0.2 mM at mid-log phase followed by growth of the cultures
for a further 4 h.
Expression and puriﬁcation of endogenous E. coli ALAD
has been described previously (Spencer & Jordan, 1993).
2.2. Purification
Native human ALAD was puriﬁed from erythrocytes using
the method of Gibbs et al. (1985) and the assay described by
Mauzerall & Granick (1956). Initially, 1.2 l of buffy coat
residues were washed in isotonic saline containing 1 mM
-mercaptoethanol (BME) followed by centrifugation at
5000 rev min1. The cells were then lysed in deionized water
containing 40 mM BME and the solution was sonicated for
60 s at medium power in an ice–water mixture prior to
removal of the cell debris by ultracentrifugation at 48 000g.
The supernatant was collected and a stock solution of 1M
potassium phosphate pH 7.5 was added to give a ﬁnal buffer
concentration of 10 mM. This solution was then mixed for
1.5 h with DEAE–BioGel A ion-exchange resin that had been
pre-equilibrated with the same buffer. The resin was collected
by centrifugation and washed three times with the buffer.
Weakly bound proteins were then removed with 50 mM KCl
in the same buffer and the more strongly bound ALAD was
eluted by the addition of 350 mMKCl. Raising the ammonium
sulfate (AS) concentration to 60% saturation allowed the
enzyme to be precipitated and separated from impurities
(mainly haemoglobin) by centrifugation at 12 000g. A buffer
solution of 100 mM potassium phosphate pH 6.8, 20 mM BME
was used to resuspend the pellet of ALAD, giving a ﬁnal
protein concentration of 30 mg ml1. Further removal of
impurities involved heat-treating the enzyme at 60C for 3 min
with stirring followed by rapid cooling to below 10C with an
ice–water mixture and centrifugation at 12 000g for 10 min.
The supernatant was removed and AS was added to 30%
saturation to precipitate ALAD, which was collected by
centrifugation, resuspended in 30 mM phosphate buffer pH
7.9 and dialysed overnight against 20 l of the same buffer. The
dialysed enzyme was applied onto a DEAE–BioGel A column
and eluted by the application of a 0–0.4M KCl gradient in
30 mM phosphate buffer pH 7.9. Active fractions were
precipitated by the addition of AS to 60% saturation and were
collected by ultracentrifugation at 48 000g prior to resuspen-
sion in 50 mM phosphate buffer pH 6.8 and a second dialysis
step against the same buffer. The protein was then loaded onto
a Bio-Rad HTP hydroxyapatite column that had previously
been equilibrated with 50 mM potassium phosphate pH 6.8
and was eluted by applying a gradient of 50–500 mM phos-
phate buffer. Active fractions were collected and concentrated
exactly as before prior to resuspension in 60 mM phosphate
buffer pH 6.8, 0.5M KCl. A ﬁnal gel-ﬁltration step was
conducted using a BioGel A-0.5M column prior to storage of
the AS-pelleted enzyme at 4C in a sealed tube under nitrogen
gas. All buffers used in the puriﬁcation included BME at a
concentration of 25 mM.
Puriﬁcation of recombinant human ALAD from the E. coli
cell supernatant involved fractional AS precipitation, with
impurities being removed by the addition of AS to 35%
saturation and the protein of interest being precipitated by the
addition of AS to 60% saturation. After dialysis, the partially
puriﬁed enzyme was applied onto a Bio-Rad hydroxyapatite
column and eluted with a linear gradient of 50–300 mM
potassium phosphate pH 6.8 containing 5 mM BME, 50 mM
ZnCl2 and 100 mM PMSF. The active fractions were pooled,
AS-precipitated and ﬁnally applied onto a Bio-Gel A-0.5M
gel-ﬁltration column.
Puriﬁcation of recombinant Pc-ALAD from the E. coli cell
supernatant involved heat treatment at a temperature of 80C
for 20 min followed by ultracentrifugation at 40 000g for
15 min to remove impurities. The Pc-ALAD was then preci-
pitated by increasing the AS concentration to approximately
35% saturation, followed by ultracentrifugation as above. The
enzyme was then dissolved in 50 mM potassium phosphate
buffer pH 7.9 containing 5 mM BME and 100 mM ZnCl2. The
dissolved protein was dialyzed against the same buffer to
remove all traces of residual AS. The protein was then
subjected to anion exchange using a HiTrap Q FF column by
applying a 0–1M NaCl gradient in the above buffer solution,
and the Pc-ALAD fractions, which eluted at around 0.4M
NaCl, were stored at 4C after dialysis to remove the NaCl.
The zinc-ion content of Pc-ALAD was determined by
atomic absorption spectrophotometry at a wavelength of
213.8 nm using an air–acetylene ﬂame. A standard curve for
zinc-ion concentrations in the range 0.00–0.03 mM was
prepared with known amounts of ZnCl2 dissolved in deionized
water. Pc-ALAD samples were prepared by extensive dialysis
against buffers devoid of zinc ions, and a protein blank was
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also made by precipitation of a 1 mg ml1 solution of Pc-
ALAD with trichloroacetic acid in order to remove any bound
zinc ions; the pellet was also washed before being dissolved in
8M urea. All samples and buffers were passed through a
syringe ﬁlter with 0.22 mm pore size before analysis.
2.3. Crystallization
For crystallization of both native and recombinant human
ALAD, the enzyme was equilibrated with 10 mM Tris pH 7.4
containing 10 mM DTTand 100 mM ZnCl2 by dialysis and was
then concentrated by centrifugal ultraﬁltration. Crystals were
grown by the hanging-drop method with the protein at a
concentration of 10 mg ml1 mixed in a 50:50 ratio with a well
solution consisting of 0.1M MES buffer in the pH range 6.2–
6.5, 1–1.6M AS and 0–10% dioxane. The resulting crystals
were cryoprotected by addition of glycerol to approximately
30%(v/v) and were cooled in a liquid-ethane bath in liquid
nitrogen.
Screening for crystallization conditions for Pc-ALAD using
the hanging-drop method involved replacing the buffer with
10 mM Tris–HCl pH 8.0 using a Vivaspin centrifugal concen-
trator. At a concentration of 5 mg ml1, the protein crystal-
lized in the presence of 1 mM laevulinic acid with 0.1M
HEPES pH 7.5, 10% 2-propanol and 20% polyethylene glycol
(PEG) 4000 in the well solution. Crystals were cryoprotected
by immersion in a mixture of parafﬁn and Paratone oil prior to
mounting in loops and were ﬂash-cooled using an Oxford
Cryosystems cryostream.
The crystallization of native E. coli ALAD has been
reported in detail previously (Erskine, Cooper et al., 1997).
Co-crystals of the enzyme with PBG were obtained using the
hanging-drop method by mixing the protein at a concentration
of 7 mg ml1 with an equal volume of well solution comsisting
of 200 mM Tris pH 8.0–8.4, 2% saturated AS, 200 mM zinc
sulfate, 6 mM BME, 3 mM PBG. The co-crystals were cryo-
protected with 30% glycerol and ﬂash-cooled in liquid ethane
prior to storage under liquid nitrogen.
2.4. Data collection and structure determination
Data collection from crystals of native human ALAD at a
temperature of 100 K was undertaken at the SRS, Daresbury,
England using beamline 9.5 equipped with a MAR Research
345 image-plate detector which was set at a distance of
475 mm from the crystal. 100 1 oscillations of the crystal were
collected with constant dose at a wavelength of 0.87 A˚ and an
image-plate scan diameter of 300 mm. Data processing with
MOSFLM (Leslie, 2006), SCALA (Evans, 2006) and other
programs in the CCP4 suite (Winn et al., 2011) yielded
intensity data to a resolution of 2.8 A˚. The crystals were
found to have two ALAD monomers per crystallographic
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Table 1
X-ray statistics for the ALAD structures.
Values in parentheses are for the outer resolution shell.
Human, native
Human,
recombinant P. calidifontis
E. coli,
PBG complex
Data collection
Beamline 9.5, SRS ID14-2, ESRF I02, DLS BM14, ESRF;
X11, DESY
Wavelength (A˚) 0.87 0.93 1.04 1.07, 0.83
Space group I422 P4212 P3121 I422
Unit-cell parameters
a = b (A˚) 125.5 127.1 205.6 128.6
c (A˚) 200.9 91.2 199.2 142.8
Mosaic spread () 0.5 0.7 0.3 0.5
Resolution (A˚) 54.2–2.8 (3.0–2.8) 29.2–2.8 (3.0–2.8) 99.6–3.5 (3.6–3.5) 36.8–2.1 (2.2–2.1)
Rmerge† (%) 7.1 (25.7) 13.4 (39.3) 11.8 (54.8) 13.1 (63.2)
Rmeas‡ (%) 8.2 (38.3) 14.2 (41.5) 13.2 (61.1) 13.7 (67.3)
Completeness (%) 96.0 (76.7) 99.7 (98.6) 100.0 (100.0) 99.9 (99.4)
Average I/(I) 6.0 (2.9) 11.1 (5.3) 14.7 (4.8) 15.9 (3.3)
Multiplicity 5.9 (3.7) 9.2 (9.1) 9.8 (9.9) 11.5 (8.4)
No. of observed reﬂections 110047 (11426) 173694 (24357) 622972 (44178) 401332 (42004)
No. of unique reﬂections 18652 (3088) 18874 (2665) 63352 (4448) 34864 (4971)
Wilson plot B factor (A˚2) 36.1 69.1 75.9 25.3
Solvent content (%) 55.2 51.9 54.2 70.3
Reﬁnement
R factor (%) 16.5 17.2 18.1 15.7
Free R factor (%) 23.8 26.5 25.1 21.3
No. of reﬂections, working set 17779 17923 60148 32987
No. of reﬂections, free set 872 973 3154 1780
Ramachandran allowed (%) 99 99 97 100
R.m.s.d., bond lengths (A˚) 0.01 0.01 0.01 0.03
R.m.s.d., bond angles () 1.6 1.6 1.7 2.5
Mean B factor (A˚2) 57.2 51.4 79.4 35.2
PDB code 5hnr 5hms 5lzl 5mhb
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ. ‡ Rmeas =
P
hklfNðhklÞ=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where I(hkl) is the mean intensity of the
N(hkl) observations Ii(hkl) of each unique reﬂection hkl after scaling.
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asymmetric unit and a solvent content of 55%. Other relevant
statistics (for all structures) are shown in Table 1. Structure
analysis by use of molecular replacement with X-PLOR
(Bru¨nger et al., 1998) and TFFC (Winn et al., 2011) using the
TIM-barrel domain of yeast ALAD (PDB entry 1aw5;
Erskine, Senior et al., 1997) as the search model was successful
and reﬁnement was undertaken by simulated annealing using
CNS (Bru¨nger et al., 1998) and later REFMAC (Murshudov et
al., 1997, 2011).
X-ray data for recombinant human ALAD were collected
to a resolution of 2.8 A˚ on beamline ID14-2 at the ESRF,
Grenoble, France using an ADSC Quantum 4 detector. A
series of 1 oscillation images were recorded with an exposure
time of 10 s per image and were processed exactly as above.
Since the crystals were not isomorphous to those of the native
enzyme, the structure was solved by molecular replacement
using the human native ALAD structure as the search model.
MOLREP (Vagin & Teplyakov, 2010) yielded a solution which
was reﬁned initially with SHELX (Sheldrick & Schneider,
1997), followed by TLS reﬁnement with RESTRAIN (Haneef
et al., 1985) and ﬁnally REFMAC (Murshudov et al., 1997,
2011).
X-ray data for Pc-ALAD were collected using station I02 at
the Diamond Light Source (DLS), Didcot, England. A series
of 1 oscillations were used to collect 190 of data from a single
crystal maintained at a temperature of 100 K using a
PILATUS 6M-F detector with an exposure time of 1 s per
image (50% transmission) and a crystal-to-detector distance
of 668.8 mm. The incident beam had a wavelength of
1.04346 A˚. Data processing was performed as above and the
structure of an octamer was determined using the molecular-
replacement program Phaser (McCoy et al., 2007) with E. coli
ALAD (PDB entry 1b4e; Erskine et al., 1999) as the search
model and was then reﬁned with REFMAC (Murshudov et al.,
1997, 2011). Since the Rfree was unsatisfactory at this stage
(>43%), an effort to improve the model was made by non-
crystallographic symmetry (NCS) electron-density averaging
and solvent ﬂattening with DM (Cowtan, 1994). This yielded
an improved map which showed evidence for additional
monomers that were not accounted for by the octameric
model. Hence MOLREP was run again with a monomeric
search model, using the reﬁned octamer as a ﬁxed input
structure, and this revealed the locations of another four
monomers which constitute exactly one half of an additional
octamer. Thus, the asymmetric unit contains 12 subunits or 112
octamers, with the other half-octamer being generated by
crystallographic symmetry.
Data for the complex of E. coli ALAD with PBG were
collected on beamline BM14 at ESRF with a MAR Research
345 image-plate detector using a 30 cm diameter scan. A series
of 120 s exposures were collected, each with a rotation angle
of 1, a wavelength of 1.069 A˚ and a crystal-to-detector
distance of 250 mm. Another data set was collected from a
different crystal at DESY, EMBL, Hamburg, Germany using
a MAR Research 30 cm image-plate detector on the X11
beamline with a wavelength 0.834 A˚. The data were collected
in two passes, one to a resolution of 2.1 A˚ (45 2 oscillations,
180 s exposures, crystal-to-detector distance 210 mm) and
another to measure previously overloaded spots at low reso-
lution (26  3 oscillations, 30 s exposures, crystal-to-detector
distance 350 mm); both used a 90 mm scan radius. The data
were processed as above and since both of the crystals were
isomorphous to the native enzyme (Erskine et al., 1999), the
bound structure of PBG was analysed by calculation of a
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Figure 2
The structure and assembly of human native ALAD. (a) The Amonomer
of the enzyme (helices coloured pale red and strands light green) looking
along the TIM-barrel axis with the large ﬂap covering the active site
facing towards the viewer. The catalytic lysine residues, 199 and 252, are
shown in ball-and-stick representation. (b) The asymmetric unit of the
structure contains a dimer, the second monomer of which (monomer B) is
less well deﬁned and is shown at the top in this view (helices cream and
strands blue). It can be seen that the large ﬂap covering the active site of
monomer B is not deﬁned. (c) The assembly of the complete ALAD
octamer with the A and B subunits coloured as in (a) and (b). The active-
site zinc ions which are present in the A monomers are indicated as grey
spheres.
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difference Fourier map following reﬁnement of a water-free
model with REFMAC (Murshudov et al., 1997, 2011).
Combining the data from both of these crystals was necessary
to give satisfactory outer shell completeness. The ligand and
solvent structure of the complex was built using Coot (Emsley
et al., 2010) between rounds of reﬁnement.
The ﬁnal reﬁned structures and reﬂection data sets have
been analysed using the validation programs PROCHECK
(Laskowski et al., 1993), SFCHECK (Vaguine et al., 1999) and
MolProbity (Lovell et al., 2003; Chen et al., 2010) and have
been deposited in the Protein Data Bank (http://
www.wwpdb.org) with the accession codes shown in Table 1.
The diffraction images are available at https://doi.org/
10.5281/zenodo.167356, https://doi.org/10.5281/zenodo.167135,
https://doi.org/10.5281/zenodo.54757, https://doi.org/10.5281/
zenodo.167137 and https://doi.org/10.5281/zenodo.51560 for
human native ALAD, human recombinant ALAD, Pc-ALAD
and for the complex of E. coli ALAD collected at the ESRF
and Hamburg, respectively. Figures showing the structures
were prepared using CueMol (http://www.cuemol.org/en), for
which the solvent-accessible surface and electrostatic poten-
tials were calculated using MSMS (Sanner et al., 1996) and
APBS (Baker et al., 2001), respectively. Subunit interface
areas were analysed by use of the PISA server (Krissinel &
Henrick, 2007).
3. Results
3.1. Human ALAD
There are two monomers in the asymmetric unit of human
native ALAD, which form a closely associated dimer that, in
combination with the crystallographic fourfold axis, forms
octamers with approximate dimensions of 108  108  78 A˚,
in accord with earlier EM studies (Wu et al., 1974; Pilz et al.,
1988). The octamer, the assembly of which is shown in Fig. 2,
can be described as a tetramer of dimers with a solvent-ﬁlled
channel running through the centre. Of the two monomers in
the asymmetric unit, monomer A is better deﬁned than the
other monomer (monomer B) in the general vicinity of the
active site. While both monomers show disorder in the loop
region 137–138 and at the C-terminal end, monomer B has
additional regions of disorder in the loops involving residues
89–93, 127–142 and 213–220, the latter being part of a large
loop region which covers the active site of the enzyme. The
basic fold of human ALAD is an (/)8 or TIM barrel that is
formed by an eight-membered cylindrical -sheet surrounded
by eight -helices. This domain has an N-terminal arm (resi-
dues 1–28) that engages with the TIM barrel of the adjacent
monomer in the dimer. The arm includes a region of distorted
310-helix (residues 7–10) followed by an -helix (residues 14–
19) denoted 1. As in all enzymes adopting the (/)8 fold,
the active site is located in an opening formed by the loops
connecting the C-terminal ends of the parallel -strands in the
barrel to their ensuing -helical segments (Cooper & Erskine,
2004). The loop regions between these  and  segments are
elaborated extensively at the active-site end of the barrel,
where the regular alternation of helices and strands is broken
by the insertion of several extra secondary-structure elements.
One example of this is the -hairpin formed, which lies
between 1 and 2. Here, the hydrogen bonds made by the
strands of this hairpin (2 and 3) mean that they are part of
the main -sheet of the molecule and provide an extension to
it at the active-site end of the barrel. Another elaboration on
the basic TIM-barrel fold is the loop covering the active site
(200–230), which includes a region of -helix involving resi-
dues 204–210 and denoted act. Finally, there is also a helix
(8) that lies between 9 and 9 in the primary sequence and,
like the other secondary-structure elements in the vicinity,
is important for quaternary interactions about the non-
crystallographic twofold axis within the dimer.
The structure of recombinant human ALAD also has two
monomers per asymmetric unit which form a symmetric arm-
around-barrel hugging dimer, as described above. This dimer
superimposes as a rigid group almost exactly with that of the
native enzyme: overall 94% of the amino acids in each dimer
superimpose with an r.m.s. deviation of 0.6 A˚, which is quite
low for the resolutions of these two structures. This suggests
that there is little difference in the relative orientations of the
constituent monomers within each dimer of the two crystal
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Figure 3
Superposition of the recombinant human ALAD monomer with yeast
and E. coli ALAD. The human enzyme is coloured pink, yeast ALAD is
coloured green and E. coli ALAD is shown in yellow. The active-site zinc
ions are indicated as grey spheres.
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forms. As for the native structure, the best-deﬁned subunit of
the recombinant ALAD dimer has arbitrarily been assigned
the letter A and the second subunit the letter B. There are
small differences between the A subunits of the two structures
in the regions of the following residues: 97–98, 128, 137–138
(which are missing in the native structure), 214–215 and 220.
There are more signiﬁcant differences in the B subunit, where
residues 83–95, 125–143 and 213–222 are missing in the native
structure. These differences between the two structures are all
in surface regions and are likely to be owing to proteolysis,
given that erythrocytes have a lifespan of around four months
(Shemin & Rittenberg, 1946), disorder in the protein molecule
or differences in the crystal contacts.
Superposition of a recombinant human ALAD monomer
with the structures of the yeast and E. coli ALADs (Fig. 3)
gives r.m.s. deviations of 0.97 A˚ (for 311 residues) and 1.48 A˚
(for 309 residues), respectively. This demonstrates that the
E. coli enzyme differs more markedly from human ALAD in
three dimensions than the yeast enzyme does and is in accord
with the sequence identities, with yeast and human ALAD
being 53% identical versus 43% for the E. coli and human
sequences. In addition to differences at the extended
N-terminus of the protein and its C-terminus, further differ-
ences are notable in an exposed loop region involving residues
39–44 and a helix (residues 60–70) which follows shortly
afterwards. Large differences also occur in the long loop
region involving residues 84–90, in the vicinity of residue 97
and in the loops involving residues 133–144, 185–190 and 213–
220. In all of these regions except for the N-terminal tail,
which plays an important role in quaternary contacts, the yeast
ALAD structure follows that of the human enzyme much
more closely than the E. coli enzyme does. The human enzyme
superimposes with the structure of mouse ALAD (PDB entry
2z0i), with an r.m.s.d. of 0.6 A˚ for 283 equivalent residues. This
very close structural similarity is in accord with the high
sequence identity of 89% for the human and mouse enzymes.
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Figure 4
The active site of human native and recombinant ALAD. Electron density contoured at 1.0 r.m.s. for the active sites of the A and B subunits of human
native ALAD is shown in (a) and (b), respectively. The A subunit has an additional feature of electron density for a ligand, which we have putatively
interpreted as a substrate molecule (ALA) bound by a Schiff base to Lys252. The active sites of the A and B subunits of the human recombinant enzyme
are shown in (c) and (d), respectively, contoured at the same level. The recombinant enzyme has better deﬁnition of the zinc-binding cysteines in both
subunits but lacks a bound substrate molecule. Note that the dative bonding to the zinc ion (grey) is only drawn in (a) since this structure possesses
electron density for the full complement of tetrahedral ligands, the fourth ligand being a water molecule.
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Comparison of the human ALAD structure with that of a
most distantly related ALAD, that from Toxoplasma gondii,
which has 40% sequence identity, reveals an additional region
of variability in the range 268–270 (human numbering) where
the parasite enzyme has a one-residue deletion. There is some
additional variability in the region of residue 290 and espe-
cially at the N- and C-termini, where the T. gondii enzyme
is more extended and has some additional elements of
secondary structure which play important roles in octamer
formation (Jaffe et al., 2011).
The active site of the A subunit of human native ALAD
contains a well deﬁned zinc ion that is coordinated by
cysteines 122, 124 and 132 (Fig. 4). The zinc ion lies close to
two invariant lysine residues, 199 and 252, which are known
from other studies to form Schiff-base links with the A-side
and P-side substrate moieties, respectively. The active site of
the A subunit also contains electron density for a ligand
molecule which appears to be bound covalently to the active-
site Lys252. In accord with previous studies of the yeast
enzyme (Erskine et al., 1999; Erskine, Newbold et al., 2001), we
have interpreted this as being the substrate ALA bound by a
Schiff-base link. In contrast, the greater disorder in the active-
site region of the B subunit renders a number of these features
invisible in the electron-density map, although Cys122 and
Cys124 are clearly resolved at positions which would allow
them to coordinate a zinc ion. However, residues of the active-
site loop from 213 to 220 of the native enzyme are disordered
and thus missing from the model, as are residues in loops from
90 to 92 and from 127 to 142. The latter region includes the
third zinc-binding cysteine (Cys132) and accordingly the zinc
ion was not modelled in this subunit. The structure of the
recombinant human enzyme exhibits similar disorder effects
in the B subunit, although all of these regions have been built
into the model and the zinc ion along with its associated
cysteines appear to well deﬁned by the electron density
(Fig. 4). The differences between the A subunits of the native
and recombinant ALADs are appreciably smaller, being
restricted to short regions which are missing from the native
enzyme between residues 137–138 and 329–330 at the
C-terminus, as well as local conformational differences in the
following regions: 97–98 and 214–220.
3.2. Comparison of octameric and hexameric human ALAD
structures
The structure of a hexameric mutant of human ALAD
(F12L; Breinig et al., 2003) showed that the constituent dimers
are each twisted by approximately 60 with respect to those of
the octameric form. In all ALAD structures the N-terminal
arm of one monomer ‘caps off’ the buried end of the TIM
barrel of one of the monomers in an adjacent dimer. In
octameric ALADs this N-terminal arm also ‘hugs’ the TIM
barrel of the neighbouring monomer in the same dimer. In
contrast, in the hexameric mutant the dimers are oriented such
that the N-terminal arm is unable to curl around the TIM
barrel of the neighbouring monomer in the dimer, although
the barrel-capping interaction with the adjacent dimer is
preserved. Thus, superposition of the octamers of all ALAD
structures from different species was undertaken to investi-
gate whether there are any relative internal movements of the
subunits owing to sequence differences and crystal-packing
effects, which might indicate how a transition between the
octameric and hexameric forms can be made. This was
undertaken by using the PISA server (Krissinel & Henrick,
2007) to generate the corresponding octamers, followed by
approximate least-squares superposition of the different
research papers
Acta Cryst. (2017). D73, 9–21 Mills-Davies et al.  Complexes of 5-aminolaevulinic acid dehydratase 17
Figure 5
The electrostatic surface of the human recombinant ALAD octamer. (a)
A cutaway view looking along the fourfold axis and emphasizing the
negative charge (red) associated with the inner channel. The positively
charged grooves associated with the outer surface of the octamer are also
apparent (blue). These can be seen to form diagonals connecting the
active sites of adjacent subunits, as shown in (b), in which the octamer is
viewed from the same direction as Fig. 2(c) with the fourfold axis vertical.
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ALAD octamers using just their P-site lysine residues for
simplicity. Viewing these as an animation, one can discern
small rotations of the TIM-barrel domains around the axes of
the barrels as well as small changes in the orientations of the
barrel axes. However, these movements do not greatly affect
the orientations of the arm-hugging dimers in the octamers
and, whilst indicating the general range of motion available to
the TIM-barrel domain of each monomer, unfortunately they
do not give an indication of how the octamer–hexamer tran-
sition is made.
The electrostatic surface of the human ALAD octamer is
generally dominated by basic and neutral residues (Fig. 5).
However, there exists a highly acidic channel running along
the fourfold axis of the assembly and this feature appears to be
conserved across the enzyme family. The negative charge of
this channel is consistent with the fact that a metal-binding site
that occurs in ALADs from some species is located within this
channel (Erskine et al., 1999; Frankenberg et al., 1999). The
diameter of the channel is in the range 15–20 A˚, which is
comparable to the pore size of transport proteins and is
suggestive of another biological function which ALAD might
have, particularly in view of its association with the protea-
some and the chaperone Hsp70. When the electrostatic
surface of the octamer is viewed from the side with the four-
fold axis vertical, there are four pronounced basic grooves
running diagonally across each face of the octamer. Each
groove connects the two outward-pointing active sites on each
side of the octamer and appears to lead directly into the
buried active-site cavity of each of the two monomers. The
active site itself also has a marked basic character. Thus, if the
substrate ALA is negatively charged, these substantial elec-
tropositive grooves, each of which has openings into the two
active sites of each dimer, could assist catalysis by electrostatic
funnelling. At physiological intracellular pH values (around
7.3), the charge of the substrate will be dominated by that of
its carboxylate group, which has a pKa of 4.0, rather than by
the amino group, which has a pKa of 7.8 and therefore is likely
to be only partially positively charged. This suggests that
electrostatic funnelling is likely to be a feature of ALAD
catalysis and is further corroborated by the fact that the main
features of the surface potential of human ALAD are
conserved across the range of octamers from species for which
ALAD structures have been determined. Alternatively, these
channels might conceivably provide sites where the product
porphobilinogen (which possesses two carboxylate groups)
could accumulate prior to transfer to the next enzyme in the
pathway, namely porphobilinogen deaminase. It is also inter-
esting that the electrostatic surface of the inactive hexameric
F12L mutant of the human enzyme is appreciably different
owing to it lacking the central acidic pore and the outer basic
grooves. Since the active sites are more central in the
hexameric form, the inner regions of this assembly have an
abundance of positive charge, although it has to be noted that
many residues in loops at the active-site end of the TIM barrel
are absent in the structure and thus were not included in the
electrostatic calculations.
3.3. P. calidifontis ALAD
Pc-ALAD expressed in E. coli was shown by mass spec-
trometry to have a molecular mass of 37 676.2  0.2 Da.
Characterization of Pc-ALAD revealed that it functions
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Figure 6
Crystal packing of Pc-ALAD. The 12 monomers which constitute the crystallographic asymmetric unit are coloured gold. These form one complete
octamer (shown on the left) and another half-octamer (shown on the bottom right). However, the crystallographic symmetry generates a complete
octamer from neighbouring monomers (shown in pale blue, top right).
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optimally in the relatively basic pH range of 7.5–9.0 and
requires exogenous thiols and zinc ions for optimal activity.
Whilst other characterized ALADs can withstand a heat shock
of 60–70C for a short time period (Jordan & Seehra, 1986),
Pc-ALAD was found to be thermostable, with a half life of
approximately 9 h at a temperature of 100C. Analysis of a
well dialyzed Pc-ALAD sample from which all the loosely
bound zinc ions had been removed gave a stoichiometry of
0.7  0.05 moles of zinc per mole of Pc-ALAD subunits.
Analysis of the X-ray diffraction obtained from Pc-ALAD
crystals revealed that they are trigonal and belong to space
group P3121, with unit-cell parameters a = b = 205.6,
c = 199.2 A˚. Molecular replacement conﬁrmed that it is an
octameric protein that has crystallized with 12 subunits or 112
octamers in the asymmetric unit, with the other half-octamer
arising from crystallographic symmetry (Fig. 6). This agrees
with the reports for other bacterial and animal ALADs, which
have been found to be octameric (Bevan et al., 1980), although
recent work has suggested the existence of a less active
hexameric form in humans (Sawada et al., 2011; Selwood et al.,
2008) and there are numerous reports that the enzyme is
hexameric in higher plants (reviewed in Boese et al., 1991).
In spite of the fact that the diffraction data for Pc-ALAD
only extend to medium resolution (3.5 A˚), the electron-
density map is of reasonably good quality throughout the
structure. This may stem partly from the beneﬁcial effects of
the high noncrystallographic symmetry, which was exploited
in density averaging and reﬁnement. The side chains of the
conserved active-site lysines (204 and 257) have good electron
density in ten of the 12 molecules in the asymmetric unit, and
the other features of the catalytic site, including the bound
zinc ion and its coordinating cysteines, are very well deﬁned in
all 12 of the subunits in the asymmetric unit. However, there
appears to be a lack of convincing electron density for the
inhibitor, laevulinic acid, which was present during crystal-
lization. In contrast, there is good electron density in all
subunits for a zinc ion bound at the site at which magnesium
ions are known to have an allosteric activating effect on the
enzyme from some species. Here, the metal ion interacts
predominantly with the side chains of Glu242 and Asp246,
although the side chains of Asp178 and Glu249 are close by.
An analysis of the subunit interfaces in the Pc-ALAD
structure using PISA (Krissinel & Henrick, 2007) indicates
that formation of the octamer involves burying around
46 510 A˚2 of surface-accessible area. This is comparable to the
values for ALADs from mesophilic organisms, such as yeast
(51 955 A˚2) and E. coli (41 860 A˚2). Since the subunits of these
three enzymes are also held together by a similar number of
salt bridges and hydrogen bonds, the basis for the extreme
thermostability of the P. calidifontis enzyme is not clear, as is
often the case in such comparisons. One slightly unusual
feature of Pc-ALAD is that the N-terminal region appears to
be appreciably buried within the inter-subunit channel which
runs along the central fourfold axis of the octamer. The
equivalent region in other ALAD structures tends to be
shorter and/or more solvent-exposed. The fact that this part of
the four monomers comes close together in a position which
essentially seals off the water-ﬁlled channel passing through
the centre of the octamer is almost redolent of the safety valve
on a boiler! Whether the N-terminal region of Pc-ALAD does
contribute speciﬁcally to the thermostability of the molecule
could, in principle, be tested by deletion mutagenesis. It is
interesting that the enzyme from T. gondii has a more
extensive elaboration at the N-terminal end, which forms a
-hairpin turn (Jaffe et al., 2011). However, this hairpin is
considerably more exposed than the N-terminal -strand of
Pc-ALAD since it appears to loop out of the mouth of the
channel passing through the octamer, rather than folding into
it. Curiously, the C-terminal end of the Toxoplasma enzyme
also has a -strand extension, which probably plays a role in
stability of the octamer by forming an antiparallel interaction
with the same strand of a neighbouring subunit.
3.4. Structure of the noncovalent complex with the product,
porphobilinogen
The complex of E. coli ALAD with the reaction product
PBG has a number of interesting features and differs signiﬁ-
cantly from a previously reported structure of yeast ALAD
with a bound PBG moiety that was covalently attached to the
P-site lysine of the enzyme (Erskine et al., 2003). The complex
with the yeast enzyme was obtained by co-crystallization with
the substrate ALA, rather than by co-crystallization with the
ﬁnal product, PBG. Thus, the covalent bond observed in the
yeast ALAD–PBG complex is likely to be a residual effect of
the Schiff-base link between the P-site lysine residue and the
ALA substrate. In contrast, the structure of E. coli ALAD
possesses a noncovalently bound PBG moiety which makes
very similar hydrogen-bonding and other interactions with the
active-site residues. The most notable interaction is a dative
bond between the pyrrole side-chain amino group and the
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Figure 7
The structure of PBG bound to E. coli ALAD. The reﬁned 2Fo  Fc
electron density for the PBG and the active-site zinc ion (grey) is shown
as blue lines contoured at 1.0 r.m.s.. The main interacting residues,
including the Schiff-base lysines in the foreground, are labelled and
hydrogen bonds are indicated by dotted lines.
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active-site zinc ion. This interaction is consistent with previous
NMR studies, which demonstrated the role of the zinc ion in
binding the A-side substrate and the reaction product (Jaffe &
Hanes, 1986; Jaffe & Markham, 1987, 1988; Jaffe et al., 1990).
Curiously, in our structure the pyrrole ring appears to be very
elegantly sandwiched between the side-chain amino groups of
both active-site lysine residues (Lys247 and Lys195) on one
side and the aromatic ring of Phe204 which resides in the short
region of helix covering the active site, act, on the other
(Fig. 7). Although there are many aromatic side chains in the
vicinity of the active site, only Phe79 and Phe204 make
hydrophobic van der Waals contacts with the pyrrole-ring
atoms. The P-side carboxyl group of PBG forms hydrogen
bonds to the side chains of Ser273 and Tyr312, and the pyrrole-
ring amino group is devoid of hydrogen-bond interactions
with the enzyme. This contrasts with the partially formed PBG
moiety bound to yeast ALAD, in which the ring amino group
appears to form hydrogen bonds to conserved serine and
aspartate residues. The equivalent residues in E. coli ALAD
(Asp118 and Ser165) are approximately 4 A˚ from the pyrrole
N atom in the noncovalent PBG complex, and this is too far
for hydrogen bonding. Superposition of the two complexes
demonstrates that the pyrrole N atom is displaced by
approximately 1 A˚ in the two complexes. The A-side carboxyl
group is within hydrogen-bonding distance of two invariant
arginine side chains (Arg205 and Arg216) and the side chain
of Gln220, suggesting that this carboxyl side group of the
pyrrole is stabilized by both polar and ionic interactions with
the enzyme.
4. Discussion
The structures of human ALAD determined from native and
recombinant protein are, as expected, substantially similar,
although the recombinant protein appears to be better deﬁned
than the native enzyme in the exposed loop regions. This
presumably correlates with the age of the protein puriﬁed
from mature human erythrocytes. These cells are anucleated
and therefore do not produce new protein molecules during
their lifespan, which can be up to 120 d. Erythrocyte proteins
may therefore experience greater degradation during this
period than those expressed heterologously in E. coli cells,
which are usually grown for a matter of hours and the protein
is then puriﬁed within a period of hours or days while stored at
low temperature. The ALADs that we have analysed are all
zinc-dependent owing to the presence of three cysteine resi-
dues which coordinate a zinc ion at the active centre. Our
analysis of the complex of E. coli ALAD with a product
molecule noncovalently bound to it demonstrates that the
side-chain amino group of PBG can occupy the fourth ligand
position of the active-site zinc ion, suggesting that the amino
group of A-side ALAwill initially be coordinated in the same
way.
The structures that we have analysed are all octameric and
possess a substantial solvent-ﬁlled channel running along the
fourfold axis of each octamer. These channels are largely
electronegative and accordingly a number of ALADs bind an
additional metal ion, usually magnesium, in the channel, and
this has an activating effect on catalysis. In contrast, the
outward-looking faces of the octamer have large electro-
positive grooves in them which lead into the active sites and
these may have a role in funnelling substrate to the catalytic
centre.
The ALAD from the hyperthermophile P. calidifontis has
an unusual feature at its N-terminal end, which forms a short
region of -strand that is substantially more buried in the
channel running along the fourfold axis of the octamer. This is
redolent of the additional secondary-structure elements which
were found in this region of the Toxoplasma enzyme (Jaffe et
al., 2011). Whilst our analysis of the P. calidifontis enzyme
does not immediately reveal the basis of its extreme thermo-
stability, it does provide a structural starting point for theor-
etical studies of this effect. For example, the use of simulation
methods for analysing dynamic ﬂexibility and static rigidity
have shed much light on the basis of the stability of proteins
from thermophilic and psychrophilic organisms (Wells et al.,
2014).
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